EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy

참고문헌 (6)

1. Zhu VW, "Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer", Trends Cancer, 5, pp.677~692 (2019)
2. Eng J, "Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFRmutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas", J Thorac Oncol, 10, pp.1713~1719 (2015)
3. Wang L, "PIK3CA mutations frequently coexist with EGFR", KRAS mutations in non-small cell lung cancer and sug- gest poor prognosis in EGFR, PLoS One, pp.2014, 9[DOI]
4. Piotrowska Z, "Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion", Cancer Discov, 8, pp.1529~1539 (2018)
5. Scheffler M, "PIK3CA mutations in nonsmall cell lung cancer(NSCLC) : genetic heterogeneity, prognostic impact and incidence of prior malignancies", Oncotarget, 6, pp.1315~1326 (2015)
6. Ahn JW, "Identification of somatic mutations in EGFR", KRAS, Genome Med, pp.2014, 6[DOI]

관련 논문AI추천